trial · primary record
Alisertib
HR+/HER2+ Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 10 |
| Primary completion | 2028-09 |
| Primary endpoint | Clinical benefit defined as partial tumor response (PR) |
| Registry ID | NCT07706179 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:07.355Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07706179
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.